Cardiovascular Medicine and Haematology articles for University of Toronto (U of T), Canada

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 68

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
1 1.00
Human heart-on-a-chip model emulates structural and functional characteristics of diastolic dysfunction and reveals a beneficial role for senolytics 1.00
3 0.11
Outcomes of a Typical Fibrotic Hypersensitivity Pneumonitis Pattern on Chest Computed Tomography 0.02
Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis. 0.03
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. 0.06
1 0.11
Intraoperative Cardiac Events in Pediatric Patients with Congenital Heart Disease Undergoing Noncardiac Procedures: Analysis of a Large Multicenter Registry. 0.11
1 0.05
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis 0.05
2 0.06
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma 0.03
Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma 0.03
1 0.01
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis 0.01
1 0.95
Human pluripotent stem cell-derived atrioventricular node-like pacemaker cells exhibit biological conduction bridge properties 0.95
1 0.20
Structural and functional pulmonary MRI to predict pulmonary exacerbations in Cystic Fibrosis 0.20
5 0.15
Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial 0.02
Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial 0.03
Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome. 0.04
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome 0.05
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. 0.02
1 0.03
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. 0.03
4 1.46
Differential Reductions in Total and Compositional PM2.5 Exposure across Socioeconomic and Demographic Groups from Emission Source Mitigation in Canada (2007–2016) 0.04
Finer Particulate Matter Exposure Disparities Exist but Vary across Pollution Concentrations 0.20
Reflection of Sectoral Emissions on Air Quality, Mortality, and Air Pollution Exposure Inequalities in a Metropolitan Context 0.57
Implications of Off-Peak Commercial Deliveries for Air Quality and Environmental Justice 0.65
5 0.54
Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome 0.02
New-onset postoperative atrial fibrillation management and outcomes: the VISION Cardiac Surgery cohort 0.04
SLC4A3-related short QT syndrome assessed in human induced pluripotent stem cell-derived cardiomyocytes: mechanisms of ventricular arrhythmia and sudden cardiac death 0.07
Arrhythmias in congenitally corrected transposition of the great arteries: an international study 0.10
Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting 0.31
5 0.17
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy 0.01
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes 0.00
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 0.04
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 0.04
Proactive vs Reactive Treatment of Hypotension During Surgery 0.08
1 0.73
Platelet Jak2 deficiency accelerates atherosclerosis with increased inflammatory response 0.73
1 0.37
Loss of RPGR disrupts motile cilia and causes primary ciliary dyskinesia by affecting F-actin dynamics 0.37
3 0.12
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. 0.02
Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. 0.06
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). 0.04
1 0.06
In silico predictions of action potential propagation in doxorubicin cardiotoxicity: A parametric study using preclinical 3D magnetic resonance imaging-based fibrotic left ventricle models 0.06
9 4.95
Regurgitant Jet Type Predicts Autograft Outcomes After the Ross Procedure in Congenital Patients 0.88
The influence of reoperation on aortic arch reconstructive surgery: Evidence from a multicenter, national registry 0.11
Comparison of myocardial mechanics after mitral valve repair with leaflet preservation versus leaflet resection: A subanalysis of the randomized Canadian Mitral Research Alliance CardioLink-2 trial 0.27
Single Incision Minimally Invasive Congenital Heart Surgery – Insights into Program Development and Outcome 1.00
Iatrogenic aortic dissection: Insights from the International Registry of Acute Aortic Dissection 0.06
Association of increased red blood cell distribution width with adverse cardiorenal outcomes after cardiac surgery 0.60
Unplanned reinterventions after congenital cardiac surgery and hospital mortality: A report from the Pediatric Cardiac Critical Care Consortium (PC4) 0.03
Extra-cardiac conduit restriction is associated with increased liver fibrosis in adolescent Fontan patients 1.00
Role of primary sternal closure in early outcomes following the Norwood procedure 1.00
5 0.70
Single-Ventricle Disease 0.06
Use of the Ross Procedure in North America 0.54
Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease Results From MINDS-ACHD 0.05
Differences in Arterial Events in Vascular Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome 0.04
Long-Acting Factor XI Inhibition and Periprocedural Bleeding An Analysis From AZALEA-TIMI 71 0.02
1 0.07
Polygenic risk of coronary artery disease for long-term survivors of breast cancer 0.07
3 0.11
Non-remnant triglyceride-rich lipoproteins due to lipoprotein lipase deficiency increase atherosclerosis in mice 0.07
Risk factors for mortality in patients with kidney failure on hemodialysis identified by proteomic analysis of CRIC and PACE studies 0.03
Association between self-reported multimorbidity and longitudinal brain Aβ deposition in Alzheimer’s disease 0.01
4 0.98
Predicting referral need for febrile children in low-resource community settings in South and Southeast Asia 0.03
Remote monitoring of heart failure exacerbations using a smartwatch 0.94
Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial 0.01
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.00
1 0.33
Lipid raft proteomics identify endothelial myosin-9 (MYH9) as a regulator of low-density lipoprotein transcytosis and atherosclerosis 0.33
1 0.10
Association of CT Features with Radiologic Patterns in Interstitial Lung Disease: Multinomial Analysis in CARE-PF. 0.10
1 0.04
Characterizing the Nasal Microbiome Using a Nasal Allergen Challenge Model 0.04
2 0.22
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial 0.19
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial 0.04
4 0.22
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy 0.10
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism 0.06
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 0.02
Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation 0.03

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.